Actively Recruiting
Study of a New Stem Cell Transplant Approach Using Post-Transplant Cyclophosphamide for Adults Aged 40 to 60 with Acquired Severe Aplastic Anemia Not Responding to Immunosuppressive Therapy
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-04-28
52
Participants Needed
26
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an optimized allogeneic hematopoietic stem cell transplantation HSCT protocol using post-transplant cyclophosphamide PTCy in adults aged 40 to 60 years with acquired severe aplastic anemia SAA that is refractory or has relapsed after first-line immunosuppressive therapy. The study addresses the poor outcomes of HSCT in this population, focusing on preventing graft versus host disease GvHD, a major cause of death following transplantation. This Phase 2 trial is sponsored by Assistance Publique - Hpitaux de Paris and aims to improve survival and reduce complications using new strategies in HSCT. The treatment involves a conditioning regimen including thymoglobulin, fludarabine, cyclophosphamide, and total body irradiation, followed by transplantation of bone marrow stem cells. Post-transplant GvHD prevention includes cyclophosphamide given on days 3 and 4, along with tacrolimus and mycophenolate starting day 5. Additional measures include rituximab to prevent Epstein Barr Virus reactivation. The stem cell source is exclusively bone marrow, with specific cell count targets and granulocyte colony-stimulating factor administered post-transplant until neutrophil recovery. Participants will undergo extensive monitoring including blood counts, graft survival, GvHD incidence, infections, organ function, immune reconstitution, and quality of life assessments at various time points up to 24 months after transplantation. The primary outcome is survival free from GvHD and relapse two years post-transplant. This comprehensive follow-up aims to assess safety, effectiveness, and long-term outcomes of the optimized HSCT protocol in this patient group.
CONDITIONS
Brief Title
Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
Research Team
R
Régis Peffault de Latour, MD PhD
J
Jérôme Lambert, MD PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here